Signal transduction pathways involving the c-Raf protein kinase are frequently activated in tumor cells. We have addressed the relevance of this activation by a loss-offunction approach. An anti-sense phosphorothioate oligonucleotide (ODN) speci®cally targeted against craf mRNA (Monia et al., 1996a) was used to block cRaf protein expression in four dierent cell lines derived from lung, cervical, prostate and colon carcinomas. Concomitant with the abrogation of c-Raf expression we observed the occurrence of classical apoptotic markers, including chromatin condensation, inter-nucleosomal DNA cleavage, annexin V binding and cleavage of PARP, which was followed by cell death, aecting most of the cell population. This induction of apoptosis occurred independent of the p53 status of the cell. These ®ndings demonstrate that c-Raf can protect tumor cells from undergoing programmed cell death, and suggest that the interference with c-Raf expression or function by ODNs or speci®c drugs could represent a powerful means for improving the ecacy of anti-cancer therapy.
The occurrence of pro-apoptotic lesions, including the deregulation of Myc or the loss of pRB, is a hallmark of oncogenesis (Evan et al., 1992) . The onset of programmed cell death (PCD) is prevented, however, by the concomitant activation of anti-apoptotic mechanisms, such as the deregulation of speci®c signal transduction cascades, the loss of p53 (Kinzler and Vogelstein, 1994) or the activation of protective Bcl-2 family members (Korsmeyer, 1995; Reed, 1996; Kroemer, 1997) . Any manipulation that would shift this intricate balance between pro-and anti-apoptotic pathways could have profound eects on the fate of a tumor cell, either on its own or in combination with conventional anti-cancer drugs. Since the Raf-Ras pathway is activated in many human tumors, we have been interested in studying its role in controlling PCD in tumor cells. This interest was fostered by two recent reports (Monia et al., 1996a, b) which showed that an anti-sense phosphorothioate oligonucleotide (ODN) speci®cally targeted against c-raf mRNA (ISIS5132) had profound eects on the growth of the human lung adenocarcinoma cell line A549 both in culture and on xenografts in nude mice. The underlying mechanisms remained, however, unclear.
In a ®rst set of experiments, we investigated whether the anti-sense ODN ISIS5132 (Monia et al., 1996a) (subsequently referred to as AS) would also reduce the expression of c-Raf protein in, and aect the growth of, other tumor cell lines. As shown by the immunoblot in Figure 1 , treatment of the lung tumor line A549, the cervical carcinoma cell line HeLa, the prostate carcinoma cell line LNCaP or the colon tumor cell line SW620 with AS led to a dramatic reduction of cRaf protein to levels below the detection limit of the assay. In contrast, a mismatched version of this ODN (Monia et al., 1996a) (termed MM in the present study) had no detectable eect relative to untreated control cells. The same cell lines were analysed for proliferation over a period of 5 days in the presence of AS or MM and in the absence of any ODN. The cell proliferation assay in Figure 2 demonstrate that AS had a clear inhibitory eect on all four cell lines whereas MM did not aect the cells to any signi®cant extent. These results con®rm previous studies using the same ODNs with A549 cells, and indicate that neither the ODN itself nor the lipid carrier exert detectable cytotoxic or cytostatic eects.
We then asked the question whether the eect of AS on cell growth might be due to the induction of PCD. We therefore analysed the AS-and MM-treated tumor cell lines for the occurrence of apoptotic markers. In this study we included four dierent processes associated with apoptosis: (i) the condensation of chromatin and nuclear fragmentation which was monitored by staining with Hoechst 33258 ( Figure  3a ), (ii) the internucleosomal cleavage of the genomic DNA, detected by agarose gel electrophoresis (`DNA laddering') ( tidylserine on the outer surface of apoptotic cells was measured by their ability to bind¯uorescein-labeled annexin V (Figure 4a ) and (iv) the cleavage of PARP, a substrate of the proteases (CASPASEs) activated during the apoptotic execution process (Nicholson & Thornberry, 1997) , detected by immunoblotting (Figure 4b) . The results of all these assays are compatible with the conclusion that AS induces PCD in A549, HeLa, LNCaP and SW620 cells. Thus, with each of these cell lines we observed clear morphological alterations to the nucleus (Figure 3a) , DNA fragmentation (Figure 3b) , staining with FITC-annexin V ( Figure  4a ) and PARP cleavage (Figure 4b) .
Previous studies have implicated Raf proteins in the protection of cells from apoptosis (Cleveland et al., 1994; Wang et al., 1994; Weissinger et al., 1997; Wojnowski et al., 1997) as well as in the induction of PCD (Blagosklonny et al., 1996; El-Ashry et al., 1997) . Apart from family member-speci®c dierences among c-Raf/Raf-1, v-Raf and B-Raf, these apparent discrepancies might re¯ect cell type-speci®c functions of, and eects on, Raf-controlled signal transduction cascades. c-Raf has a positive regulatory role in at least two signal transduction pathways. These functions of c-Raf include (i) the phosphorylation and stimulation of MAP kinase (Karin, 1995; Marshall, 1995) and (ii) the interaction with, and phosphorylation of, certain Bcl-2 family member (Wang et al., 1994; Wang et al., 1996a, b) . While the former function of c-Raf is largely concerned with the stimulation of proliferation rather than playing a role in apoptosis (Chen et al., 1996) , the latter event seems to be mainly associated with the inhibition of PCD, even though the precise role of c-Raf in this process remains to be investigated.
At least for the carcinoma cells analysed in the current study, c-Raf appears to have a protective role. It is unclear at present what the cellular pathways involved in this response are. It might be possible that the loss of c-Raf following AS treatment leads to an abrogation of the protective role of Bcl-2 and/or other anti-apoptotic family members, or alternatively, to a stimulation of pro-apoptotic Bcl-2 related proteins. This hypothesis suggests a role for c-Raf at a late stage in the apoptotic process, i.e., during or immediately prior to the execution phase. Such a function would also be compatible with the fact that the AS-induced PCD appears to be p53-independent (as in HeLa and SW620 cells), since p53 is thought to act earlier during the apoptotic process, i.e. during the commitment phase. Based on the results obtained in the present study, these open questions can be addressed in future studies analysing the eect to ectopically expressed Bcl-2 family members on AS-induced PCD. At this point, however, it cannot be excluded that an inhibition of the MAP kinase pathway by AS leads to the induction of PCD, perhaps by perturbing the balance of cell cycle regulatory mechanisms. In this context it is noteworthy that AS can also induce PCD in normal cells [WI-38 ®broblasts and human umbilical vein endothelial cells (HUVECs); QCL, unpublished observations], but these cells are less sensitive to AS than the tumor cells tested in the present study. This lower sensitivity, however, seems to be associated with a less ecient inhibition of c-Raf protein synthesis, since higher concentrations of AS, which completely abrogate c-Raf protein expression, induce PCD in WI-38 cells and HUVECs as eciently as in tumor cells (QCL, unpublished observations).
Finally, our observations also have practical implications. Taken together with previous data (Monia et al., 1996a) our ®ndings validate the c-Raf kinase as a target for the development of new antitumor drugs. In addition, it is possible that such drugs (including AS) might be useful to sensitize tumors to the therapeutic eect of conventional radiation-and drug-based cancer therapies.
